NCT05570708View on ClinicalTrials.gov

The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training

NAEnrolling by invitationINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

June 1, 2029

Study Completion Date

June 1, 2029

Conditions
Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD
Interventions
DRUG

MDMA, LSD, psilocybin

"* MDMA per os (2 x 100mg) in a group setting~* LSD per os (75 and 150 mcg) in a 1:1 setting~* Psilocybin per os (15 mg and 25 mg) in a group setting~* Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting"

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
collaborator

Swiss Medical Society for Psycholytic Therapy

OTHER

lead

Felix Mueller

OTHER

NCT05570708 - The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training | Biotech Hunter | Biotech Hunter